The Applications of Bioprinting with Alpha & Omega...

Life Sciences Research

3Dynamic Systems is currently developing a range of 3D bioprinted vascular scaffold as part of its new product line. We have been developing 3D bioprinting as a research tool since 2012 and have now pushed forward with the commercialisation of the first 3D tissue structures. Called the vascular scaffold, it is the first commercial tissue product to be developed by us. 3DS research has accelerated recently and work is now focussing on the fabrication of heterogeneous tissues for use in surgery.

3D Bioprinted Vessels

Over the next two years we will begin the long road towards the commercialisation of our 3D bioprinted vessels. Further development of their technology will harness tissues for operative repair and in the short-term tissues for pharmaceutical trials. This next step in the development of this process could one day transform the field of reconstructive medicine which may lead to direct bioengineering replacement human tissues on-demand for transplantation.

The next opportunity for our research is in developing organ on a chip technology to test drugs and treatments. So far we have initial data based on our vascular structures. In the future this method may be used to analyse any side-effects of new pharmaceutical products.

Surgical Therapy & Transplantation

Currently we manufacture 20mm length sections of bioprinted vessels, which if successful will lead to larger and more complex vessels to be bioprinted in 3D. Our research concentrates on using the natural self-organising properties of cells in order to produce functional tissues.

At 3DS, we have a long-term goal that this technology will one day be suitable for surgical therapy and transplantation. Blood vessels are made up of different cell types and our new Omega allows for many types of cells to be deposited in 3D. Biopsied tissue materials is gathered from a host, with stem cells isolated and multiplied. These cells are cultured and placed in a bioreactor, which provides oxygen and other nutrients to keep them alive. The millions of cells that are produced are then added to our bioink and bioprinted into the correct 3D geometry.

The Future

3Dynamic Systems building 3D bioprinters that automatically produce 3D tissue structures. The company also build perfusion bioreactors that test tissue structures over periods of months for the effects of stimulation and the test the influence of drugs on 3D cell behaviour.

3DS was founded in 2012 by Dr. Daniel J. Thomas as an early-stage research company, which produces functional three-dimensional human tissues. These are used for medical research and in the future, therapeutic applications. The company uses its internally developed 3DS Omega Bioprinter for 3D bioprinting.